Your Waterstones card is changing, introducing...
TELL ME MORE
Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease I: Markers and General Problems of Cancer Adjuvant Therapies - Recent Results in Cancer Research 67 (Paperback)
  • Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease I: Markers and General Problems of Cancer Adjuvant Therapies - Recent Results in Cancer Research 67 (Paperback)
zoom

Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease I: Markers and General Problems of Cancer Adjuvant Therapies - Recent Results in Cancer Research 67 (Paperback)

(editor), (editor), (editor)
£114.00
Paperback 154 Pages / Published: 08/12/2011
  • We can order this

Usually despatched within 3 weeks

  • This item has been added to your basket
P. Denoix and G. Mathe Approximately 70% of cancer patients relapse after surgery before the 5th year and, in most cases, for example in breast carcinoma, they relapse still later up to the 20th year. For some considerable time, the strategy of cancer treatment has been limited to the sophistication of surgery-radiotherapy combinations that maximally decreased the incidence of local and regional relapses in sites that were within their reach. Today, the practice of clinical oncology is unthinkable without the active participation of the medical oncologist. He is the "third man" of the clinical oncology team, and he has recently focused attention on the fact that most relapses arise from distant metastases due to the proliferation of cells seeded there after having left the primary tumor site at the time of operation and, hence, are inaccessible to any form oflocal and/or regional treatment. On this evidence, medical oncologists have proposed the application of medical treatments for disseminated minimal residual disease (MRD). They have two available means: chemother- apy and immunotherapy. Medical oncologists in general can be divided into three groups: chemotherapists, immunotherapists, and chemoimmunotherapists. The pure chemotherapists, who had already cured some malignant neoplasias such as Hodgkin's disease, acute lymphoid leukemia, placental choriocarcinoma, and Wilms' tumor, thought they might have the means of attacking the residual disease of common cancers.

Publisher: Springer-Verlag Berlin and Heidelberg GmbH & Co. KG
ISBN: 9783642813221
Number of pages: 154
Weight: 422 g
Dimensions: 244 x 170 x 9 mm
Edition: Softcover reprint of the original 1st ed. 197

You may also be interested in...

When I Die
Added to basket
£8.99
Paperback
The Cancer-Fighting Diet
Added to basket
Laws of Medicine
Added to basket
Cancer Virus
Added to basket
How Football Saved My Life
Added to basket
Oxford Handbook of Oncology
Added to basket
£34.99
Part-work (fascículo)
Survival Lessons
Added to basket
The Biology of Cancer
Added to basket
B is for Breast Cancer
Added to basket
Lecture Notes: Oncology
Added to basket
Beat Cancer
Added to basket
£14.99
Paperback
Oxford Handbook of Clinical Haematology
Added to basket
£34.99
Part-work (fascículo)
The Cancer Survivor's Companion
Added to basket
After Cleo, Came Jonah
Added to basket

Reviews

Please sign in to write a review

Your review has been submitted successfully.